# Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Source: https://onco.cc/trials/nct05205330/  
OnCo record `nct05205330` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Balstilimab in colorectal cancer and gastric & gastro-oesophageal junction cancer, run by Rottapharm Biotech, active and no longer recruiting.

## Summary

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers is a phase 1/2 interventional study registered as NCT05205330 by Rottapharm Biotech, with 107 participants enrolled, started 2021-11-23 and due to reach its primary completion in 2026-12. Interventions recorded: CR6086 and AGEN2034.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05205330
- Phase: 1/2
- Setting: An Open-label, Single-arm, Phase Ib/IIa Trial to Evaluate the Safety and Efficacy of the EP4 Receptor Antagonist Vorbipiprant (CR6086) in Combination With the PD-1 Inhibitor Balstilimab (AGEN2034), in Patients With Pretreated Mismatch-repair-proficient and Microsatellite Stable Metastatic Colorectal Cancer, and Other Metastatic GI Cancers.
- Sponsor: Rottapharm Biotech
- Enrolled: 107

## Sources

- ClinicalTrials.gov NCT05205330: https://clinicaltrials.gov/study/NCT05205330

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/)
- companies: [Agenus](https://onco.cc/companies/agenus/)

---
JSON: https://onco.cc/api/v1/entities/nct05205330.json